Pharmacogenetic assessment of antipsychotic-induced movement disorders: Contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes

Journal of Biochemical and Biophysical Methods

Volumn 47, Issue 1-2, 2001, Pages 151-157

  Özdemir, Vural ^a,b   Basile, Vincenzo S ^a   Masellis, Mario ^a   Kennedy, James L ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Antipsychotics; CYP1A2; Cytochrome; Dopamine D3 receptor gene; Drug metabolism; Drug safety; Pharmacogenetics; Tardive dyskinesia

Indexed keywords

CYTOCHROME P450 1A2; DOPAMINE 3 RECEPTOR;

CLINICAL FEATURE; CONFERENCE PAPER; DISEASE COURSE; DRUG METABOLISM; DRUG SAFETY; GENETIC RISK; GENOTYPE; HUMAN; INVOLUNTARY MOVEMENT; LONG TERM CARE; MOTOR DYSFUNCTION; OROFACIAL DYSKINESIA; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA;

ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP1A2; DYSKINESIA, DRUG-INDUCED; GENOTYPE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RISK FACTORS; SCHIZOPHRENIA; VARIATION (GENETICS);

EID: 0035969937     PISSN: 0165022X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-022X(00)00161-5     Document Type: Conference Paper

References (26)

1. Incidence of adverse drug reactions in hospitalized patients: Meta-analysis of prospective studies
2. Tardive dyskinesia: Prevalence and risk factors, 1959 to 1979
3. Possible genetic factors underlying the pathophysiology of tardive dyskinesia
4. Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment
5. Dopamine and serotonin system genes may predict clinical response to clozapine
6. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients
7. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia
8. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia
9. Search for a susceptibility locus to tardive dyskinesia
10. D3 dopamine receptor mRNA is widely expressed in the human brain
11. Effects on locomotor activity after local application of D3 preferring compounds in discrete areas of the rat brain
12. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice
13. Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex
14. Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders
15. Proposed schizophrenia-related gene polymorphism: Expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system
16. Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders, CNS
17. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
18. The relationship between paroxetine and the sparteine oxidation polymorphism
19. Effects of smoking on fluphenazine clearance in psychiatric inpatients
20. Cigarette smoking and chlorpromazine disposition and actions
21. Chlorpromazine plasma levels, adverse effects, and tobacco smoking: Case report
22. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine
23. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: Association with tardive dyskinesia in schizophrenia
24. Pharmacogenetics of antipsychotic treatment: Lessons learned from clozapine
25. Biotransformation enzyme polymorphism and pesticide susceptibility
26. The emerging field of ecogenetics